Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — Q3 FY26 Earnings Presentation
48 slides from Suraksha Diagnostic's earnings presentation, 2026
Slide 1: Suraksha Diagnostic Limited Investor Presentation Q3 & 9M FY26
SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q3 & 9M FY26
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 3: Q3 & 9M FY26 Highlights
Suraksha Clinic & Diagnostics Q3 & 9M FY26 Highlights
Slide 4: Management Commentary on Q3 and 9M FY26 Results
Management Commentary on Q3 and 9M FY26 Results We delivered strong financial performance this quarter with revenue rising 30% YoY, resulting in 22% growth for the 9-month period. This is driven largely by the aggressive rollout of our expansion plan. Our expansion is well underway with 12 centres f
Slide 5: Business at a Glance
Business at a Glance as of 31 December 2025 8 1.07 million 6.18 million ₹ 286 million Labs Patients Served Tests Performed Revenue per lab (9M FY26) (9M FY26) (9M FY26) 66 16 29 ₹ 2,140 Diagnostic Centres MRI Machines Revenue per patient CT Machines (9M FY26) 173 4 360 ₹ 686 NABL accredited EBITDA p
Slide 6: Key Financial Performance for Q3 FY26
Key Financial Performance for Q3 FY26 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 31.7% 31.7% 30.6% 10.1% 11.2% 9.3% +30% +26% +21% 796 783 250 88 238 72 601 189 60 Q3 FY25 Q2 FY26 Q3 FY26 Q3 FY25 Q2 FY26 Q3 FY26 Q3 FY25 Q2 FY26 Q3 FY26 Suraksha Diagnostic Limited| Investor Presentat
Slide 7: Key Financial Performance for 9M FY26
Key Financial Performance for 9M FY26 Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 34.8% 32.1% 12.7% 11.0% +22% +13% +6% 2,314 734 252 238 651 1,900 9M FY25 9M FY26 9M FY25 9M FY26 9M FY25 9M FY26 Suraksha Diagnostic Limited| Investor Presentation 7
Slide 8: Key Operating Metrics for 9M FY26
Key Operating Metrics for 9M FY26 Number of Centres Number of patients (million) Number of Tests (million) 66 1.07 6.18 53 0.90 4.86 9M FY25 9M FY26 9M FY25 9M FY26 9M FY25 9M FY26 Revenue / Patient (₹) EBITDA / Patient (₹) 2,140 725 2,084 686 9M FY25 9M FY26 9M FY25 9M FY26 Suraksha Diagnostic Limi
Slide 9: Statement of Profit & Loss (Consolidated)
Statement of Profit & Loss (Consolidated) Particulars (₹ million) Q3 FY26 Q3 FY25 Y-o-Y Q2 FY26 Q-o-Q 9M FY26 9M FY25 Y-o-Y Revenue from Operations 776.87 595.13 787.29 2,290.03 1,869.98 Other Income 6.22 5.99 8.51 23.79 30.29 Total Revenue 783.09 601.12 30.3% 795.80 -1.6% 2,313.81 1,900.27 21.8% Co
Slide 10: EBITDA Margin (%) Breakdown by Center Age
EBITDA Margin (%) Breakdown by Center Age Q1 FY26 Q2 FY26 Q3 FY26 Average EBITDA Average EBITDA Average EBITDA Revenue Margin (%) Revenue Margin (%) Revenue Margin (%) per centre per centre per centre (₹ million) 34.0% (₹ million) 31.7% (₹ million) 30.6% 42 centres > 2 yrs 15.64 38.2% 16.54 36.9% 16
Slide 11: Efficiency Gap between Mature and New Centres
Efficiency Gap between Mature and New Centres Average Monthly Revenue per centre (₹ million) 6 50.0% 5 40.0% 30.0% EBITDA Margin (%) 4 20.0% 3 10.0% 2 0.0% 1 -10.0% 0 -20.0% Mature centres (> 2 yrs) New centres (< 2 yrs) Suraksha Diagnostic Limited| Investor Presentation 11
Slide 12: Key Developments
Suraksha Clinic & Diagnostics Key Developments
Slide 13: Expanded Offerings Through Strategic Acquisition
Expanded Offerings Through Strategic Acquisition ABOUT FETOMAT • Incorporated in May 2021, Fetomat Wellness Private Limited (“Fetomat”) is a network of fertility and pregnancy care clinics • Fetomat focuses on pregnancy care, women’s ultrasound scans, prenatal diagnostics, genetic counselling and me
Slide 14: Genomics could be the Next Growth Lever
Genomics could be the Next Growth Lever About Genomics Vertical Global Genetic Testing Market Size ($ billion) 186.64 • In July 2025, we announced the launch of Suraksha Genomics, a new vertical for advanced genetic and molecular testing services • Suraksha Genomics offers robust infrastructure and
Slide 15: Genomic Lab Suraksha - Your blueprint for life, secured
Genomic Lab Suraksha- Your blueprint for life, secured The Suraksha advantage Why choose Genomic Lab Suraksha? We don't just sequence DNA; we protect our patient’s most personal o Speed: data while delivering life-altering insights. Rapid TAT (Turnaround Time) for critical neonatal and oncology repo
Slide 16: Strategy & Expansion
Clinic & Diagnostics Strategy & Expansion
Slide 17: Expansion Plans – Centres FY26
Expansion Plans – Centres FY26 Breakdown of Launches By Center Age and Location Hub Centre Spoke Centre Public Private Partnership (PPP) 2 7 2 H1 FY26 Baruipur, Ranaghat Naihati, Shantipur, Gorabazar, S. D. Hospital – Durgapur & Kharagpur Kanchrapara, Fetomat - 2 & Ekbalpur 3 Q3 FY26 - Shyambazar, S
Slide 18: Glimpses of Centre Expansion in 9M FY26 (1/2)
Glimpses of Centre Expansion in 9M FY26 (1/2) Suraksha Diagnostic Limited| Investor Presentation 18
Slide 19: Glimpses of Centre Expansion in 9M FY26 (2/2)
Glimpses of Centre Expansion in 9M FY26 (2/2) Suraksha Diagnostic Limited| Investor Presentation 19
Slide 20: Company Overview
Suraksha Clinic & Diagnostics Company Overview
Slide 21: Vision, Mission and Values
Vision, Mission and Values Medium-term Long-term We aspire to metamorphise the Company into the most reputable and Our vision is to be the most trusted and innovative diagnostic centre and cutting-edge diagnostic facility, providing precise, prompt, affordable set the standard for diagnostics in the
Slide 22: Evolution to the Largest Integrated Diagnostic Chain in East India
Evolution to the Largest Integrated Diagnostic Chain in East India Received second round of funding from OrbiMed Exit of Lighthouse Funds IPO and listing on Built fully BSE and NSE comprehensive diagnostic centre, 4 Labs 9 Labs under brand ‘Suraksha’ 1 centre 5 centres 25 centres 53 centres 66 centr
Slide 23: Deeply Entrenched in the Vital Geography of West Bengal
Deeply Entrenched in the Vital Geography of West Bengal 64 Centers in West Bengal 2 1 No. of centres >10 centres 1 4 to 10 centres 3 centres 2 centres Bihar Assam 1 centre • 4th most populous state in India • Fragmented market with low penetration of Meghalaya Population Legend chained diagnostic ce
Slide 24: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & employees / centre Area Hub Centres Large MRI Gastroenterology Dexa OPG Mammo Centres 30-40 5,000 – 8,000 sq. ft CT Scan Neurology USG X-Ray Cardiology Pathology Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan Neurology USG X-
Slide 25: With Demonstrated Success
…..With Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 7 Satellite Labs 16 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 26: Well-established Operational Network - Greater Economies of Scale
Well-established Operational Network - Greater Economies of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #16 #1 Hub Centre Flagship Reference Lab Doctor #7 #45 SATELLITE LAB Spoke Centre Customers Polycli ni c Doct or Samples C
Slide 27: Well Equipped Clinical Infrastructure
Well Equipped Clinical Infrastructure Suraksha Diagnostic Limited| Investor Presentation 27
Slide 28: Customer Convenience Through Value Added Services
Customer Convenience Through Value Added Services Value Added Services enhancing customer experience and convenience Home Collection Allows samples to be collected from the consumers’ locations, such as their homes or offices SMS Alerts Customers receive an SMS to Customer download the report throug
Slide 29: Positioned to Leverage IT Infrastructure
Positioned to Leverage IT Infrastructure Suraksha’s Integrated System for Diagnostics LIMS Integration RIS and PACS Advanced ERP-enabled Error Reduction and Workflow Imaging Tools Operations Turnaround Time Our Laboratory The Radiology PACS includes DICOM Our ERP system handles Automation reduces In
Slide 30: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services % of 9M FY26 Revenue 48% 46% 6% Pathology Radiology Other 160+ 1,000+ Chambers1 Doctors1 Omnichannel medical consultation services via online and offline modes through Other includes Revenue from Doctor Consultancy
Slide 31: Experienced Board Of Directors
Experienced Board Of Directors Dr. Somnath Chatterjee Ritu Mittal Mr. Satish Kumar Verma Chairman & Joint Managing Director Joint Managing Director & Chief Non-Executive, Non-Independent Director Executive Officer ▪ Associated with Suraksha since ▪ 40+ years of experience in management incorporation
Slide 32: Dynamic And Diverse Management Team to Deliver Next Phase of Growth
Dynamic And Diverse Management Team to Deliver Next Phase of Growth Ravindra K S Mamta Jain Niren Kaul Group Chief Financial Officer Company Secretary & Compliance Officer Chief Sales Officer ▪ Professional with over 20 years of extensive experience in ▪ 22+ years of experience, including with Bhart
Slide 33: Marquee Shareholders Invested in our Story
Marquee Shareholders Invested in our Story Shareholding Pattern as at 31 December 2025 13.46% 49.00% 22.56% 14.98% Promoter & Promoter Group FIIs DIIs Others Source: BSE DIIs include Mutual Funds, AIFs and Central / State governments FIIs include Foreign Direct Investments and Foreign Portfolio Inve
Slide 34: Key Awards & Recognition
Key Awards & Recognition 2017 2019 2021 Best quality in service delivery(1) Best customer service in healthcare(1) Business leader of the year (2) 2021 2022 2023 Certificate of excellence Outstanding diagnostic chain of Awards & certificate of excellence(3) in exemplary trust & commitment eastern In
Slide 35: Strategy & Outlook
Clinic & Diagnostics Strategy & Outlook
Slide 36: Leveraging Strengths to Drive Competitive Advantage
Leveraging Strengths to Drive Competitive Advantage Largest diagnostic chain with a Technologically advanced Track record of profitability dominant position in Eastern clinical infrastructure and and consistent financial India; well-positioned to benefit trained personnel ensuring performance from t
Slide 37: Strategic Levers to Drive Future Growth
Strategic Levers to Drive Future Growth Expand footprint in Eastern and Enhance one-stop diagnostic North-Eastern India through model by augmenting medical organic as well as inorganic consultation services’ share route Strengthen B2B and Invest in technology to institutional partnerships to enhance
Slide 38: Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Identi
Slide 39: Industry Overview
Clinic & Diagnostics Industry Overview
Slide 40: Industry: Poised For High Growth; Shifting Towards Organized Market
Industry: Poised For High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 41: Eastern India - An Underserved Market With Premium Pricing
Eastern India - An “Underserved” Market With Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 42: Historical Financials and Operating Metrics
Historical Financials and Operating Metrics
Slide 43: Consolidated Financial Performance – Historical
Consolidated Financial Performance – Historical Total Income (₹ million) EBITDA (₹ million) PAT (₹ million) 25.0% 33.7% 33.8% 3.2% 10.6% 12.3% +32% +79% +411% 2,559 851 310 2,223 736 1,937 231 475 61 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Suraksha Diagnostic Limited| Investor Presentation 43
Slide 44: Consistent Performance Over the Years
Consistent Performance Over the Years Number of Centres Number of Patients (million) Number of Tests (million) 55 1.14 1.19 6.69 48 1.11 5.98 43 5.17 FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 Revenue / Patient (₹) EBITDA / Patient (₹) ROE % ROCE % +24% +67% 2118 1922 715 16.29 23.30 1712 647 21.4
Slide 45: Statement of Profit & Loss (Consolidated)
Statement of Profit & Loss (Consolidated) Particulars (₹ million) FY25 FY24 FY23 FY25 vs FY24 FY23-25 CAGR (%) Revenue from Operations 2520.93 2187.09 1901.34 Other Income 38.46 35.51 35.53 Total Revenue 2559.39 2222.59 1936.87 15.2% 15.0% Cost of Material Consumed 295.19 272.51 274.04 Employee Bene
Slide 46: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Particulars (₹ million) FY25 FY24 FY23 Particulars (₹ million) FY25 FY24 FY23 Assets Equity Equity share capital 104.16 69.00 69.00 Non-current assets Instruments entirely equity in nature - 16.29 16.29 Property, plant and equipment 1,471.37 1,350.50 1,127.89 Other equit
Slide 47: Statement of Cash Flows (Consolidated)
Statement of Cash Flows (Consolidated) Particulars (₹ million) FY25 FY24 FY23 Profit before Tax 414.05 314.53 67.48 Adjustment for Non-Operating Items 428.61 413.29 397.12 Operating Profit before Working Capital Changes 842.67 727.82 464.6 Changes in Working Capital -103.26 -36.9 48.29 Cash Generate
Slide 48: Thank You
Company : Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Email: investors@surakshanet.com investors@surakshanet.com Investor Relations Advisors : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services Mr. Ashish Tendulkar ashish.tendu